极晚期实体瘤患者的全身抗癌治疗与总生存期
这项全国性队列研究利用Flatiron Health数据库纳入2015至2019年144家机构78 446例转移性或晚期实体瘤成人患者,按机构层面NQF 0210(生命最后14天接受化疗)率五分位分组,比较各组总生存期;最高与最低五分位组间生存无统计学显著差异,经Bonferroni校正后差异均不显著。
要点
- 研究纳入6种常见癌症共78 446例患者,机构NQF 0210率从五分位1至5差异明显。
- 最高与最低NQF 0210五分位组间总生存期无统计学显著差异(Bonferroni校正P=.008)。
- 肾细胞癌风险比0.74(95%CI 0.55-0.99),尿路上皮癌1.41(95%CI 0.98-2.02),均未达校正后显著。
核心结论
- 在转移性或晚期癌症患者中,就诊于NQF 0210率较高机构的患者总生存期并未改善。
研究设计与样本
- 全国性基于人群的队列研究,使用Flatiron Health去标识电子健康记录数据库,纳入2015至2019年在144家医疗机构治疗的78 446例成人(≥18岁)转移性或晚期6种常见癌症患者。
- 按回顾性测量的NQF 0210率将机构分为五分位,从转移诊断时起采用多变量Cox比例风险模型比较各五分位组总生存期,并对多重比较进行Bonferroni校正。
- 数据分析时间为2021年7月至2023年7月。
主要发现
- 患者平均(SD)年龄67.3(11.1)岁,女性占52.2%;最常见类型为非小细胞肺癌34 201例(43.6%)和结直肠癌15 804例(20.1%)。
- 机构层面NQF 0210率:非小细胞肺癌从五分位1的10.9%至五分位5的32.3%,结直肠癌从五分位1的6.8%至五分位5的28.4%。
- 与最低NQF 0210五分位机构相比,最高五分位机构患者死亡风险比从肾细胞癌的0.74(95%CI 0.55-0.99)至尿路上皮癌的1.41(95%CI 0.98-2.02)。
- 应用Bonferroni校正临界P=.008后,上述差异均未达统计学显著。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Two prominent organizations, the American Society of Clinical Oncology and the National Quality Forum (NQF), have developed a cancer quality metric aimed at reducing systemic anticancer therapy administration at the end of life. This metric, NQF 0210 (patients receiving chemotherapy in the last 14 days of life), has been critiqued for focusing only on care for decedents and not including the broader population of patients who may benefit from treatment. OBJECTIVE: To evaluate whether the overall population of patients with metastatic cancer receiving care at practices with higher rates of oncologic therapy for very advanced disease experience longer survival. DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based cohort study used Flatiron Health, a deidentified electronic health record database of patients diagnosed with metastatic or advanced disease, to identify adult patients (aged ≥18 years) with 1 of 6 common cancers (breast cancer, colorectal cancer, non-small cell lung cancer [NSCLC], pancreatic cancer, renal cell carcinoma, and urothelial cancer) treated at health care practices from 2015 to 2019. Practices were stratified into quintiles based on retrospectively measured rates of NQF 0210, and overall survival was compared by disease type among all patients treated in each practice quintile from time of metastatic diagnosis using multivariable Cox proportional hazard models with a Bonferroni correction for multiple comparisons. Data were analyzed from July 2021 to July 2023. EXPOSURE: Practice-level NQF 0210 quintiles. MAIN OUTCOME AND MEASURE: Overall survival. RESULTS: Of 78 446 patients (mean [SD] age, 67.3 [11.1] years; 52.2% female) across 144 practices, the most common cancer types were NSCLC (34 201 patients [43.6%]) and colorectal cancer (15 804 patients [20.1%]). Practice-level NQF 0210 rates varied from 10.9% (quintile 1) to 32.3% (quintile 5) for NSCLC and 6.8% (quintile 1) to 28.4% (quintile 5) for colorectal cancer. No statistically significant differences in survival were observed between patients treated at the highest and the lowest NQF 0210 quintiles. Compared with patients seen at practices in the lowest NQF 0210 quintiles, the hazard ratio for death among patients seen at the highest quintiles varied from 0.74 (95% CI, 0.55-0.99) for those with renal cell carcinoma to 1.41 (95% CI, 0.98-2.02) for those with urothelial cancer. These differences were not statistically significant after applying the Bonferroni-adjusted critical P = .008. CONCLUSIONS AND RELEVANCE: In this cohort study, patients with metastatic or advanced cancer treated at practices with higher NQF 0210 rates did not have improved survival. Future efforts should focus on helping oncologists identify when additional therapy is futile, developing goals of care communication skills, and aligning payment incentives with improved end-of-life care.
引用
- Canavan ME, Wang X, Ascha MS, et al. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024. PMID: 38753341. doi:10.1001/jamaoncol.2024.1129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。